Covidien Expects Continued Growth In Neurovascular Division
Executive Summary
With more than $30 million invested in stroke clinical trials and technology, Covidien sees tremendous opportunity in the endovascular treatment of acute ischemic stroke. The company’s ongoing research is laying the foundation for continued growth in its neurovascular division.
You may also be interested in...
Endovascular Devices Headline International Stroke Conference
The American Heart Association-sponsored conference in Nashville featured late-breaking presentations of data from several major neurointerventional device trials as well as meta-analysis and pooled results confirming the benefits of endovascular intervention in several difficult-to-treat populations of stroke patients.
Stroke Devices: Hope Amid Headwinds
Despite market headwinds, the endovascular treatment of acute ischemic stroke remains a growing and highly under-penetrated market opportunity valued at more than $1 billion worldwide. Although advances in neurothrombectomy devices, access catheters, imaging, and neuroprotective therapies have the potential to help expand the treatable population, positive Level I clinical evidence is needed to drive adoption and market growth.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.